Abstract
The apolipoprotein E4 (APOE4) allele is the most significant genetic risk factor for late-onset Alzheimer's disease (AD). Emerging evidence suggests that the proteolytic fragmentation of ApoE4, resulting in a toxic gain-of-function, may be a critical molecular driver of AD pathology. Previous research identified a 151 amino-terminal fragment of ApoE4 (nApoE4$_{1-151}$) that localizes to the nuclei of microglia in human AD brains and triggers inflammatory activation in vitro. This study compares the transcriptomic profiles of BV2 microglia cells treated with either full-length ApoE4 (FL-ApoE4) or the nApoE4$_{1-151}$ fragment. Our results demonstrate that while the fragment induces massive up-regulation of over 1,600 genes related to inflammation, the full-length protein remains relatively inert, affecting only 48 genes. These findings suggest that the conversion of microglia to a pro-inflammatory phenotype requires the proteolytic cleavage of FL-ApoE4, highlighting a potential therapeutic target for AD.
Introduction
While the link between APOE4 and Alzheimer’s Disease is well-established, the precise mechanism by which this lipid-transport protein contributes to neurodegeneration remains unclear. The "toxic gain-of-function" hypothesis posits that the primary pathological agent is not the intact protein, but rather specific fragments generated by enzymatic cleavage.
This study addresses whether fragmentation is the necessary "switch" for microglial activation. By comparing the gene expression profiles of microglia exposed to both the full-length protein and its 151 amino-acid amino-terminal fragment, researchers sought to determine if the full-length protein possesses the same inflammatory potential as its truncated counterpart.
Methods
The study utilized BV2 cells, a murine microglial cell line, treated with 25 µg/ml of either human FL-ApoE4 or the nApoE4$_{1-151}$ fragment. The experimental workflow included:
- Immunocytochemistry: Fluorescent labeling was used to visualize the intracellular localization of the ApoE4 variants.
- RNA-sequencing (RNA-seq): Global gene activity was captured using an Illumina HiSeq4000 platform.
- Bioinformatics: Reads were mapped to the mouse reference genome (GRCm39), and differentially expressed genes (DEGs) were identified using DESeq2 (p < 0.05, > 2-fold change).
- Functional Analysis: The PANTHER classification system was employed for Gene Ontology (GO) analysis to categorize the biological roles of the identified DEGs.
Key Insights and Results
Differential Cellular Localization
A critical finding of this study is the distinct spatial distribution of the two protein forms. The nApoE4$_{1-151}$ fragment exhibits strong nuclear localization, suggesting it may function as a transcription factor or nuclear modulator. In contrast, FL-ApoE4 remains primarily sequestered in the cytoplasm.
Transcriptomic Impact: Fragment vs. Full-Length
The transcriptomic response to FL-ApoE4 was remarkably minimal compared to the fragment. Only 48 DEGs were identified for FL-ApoE4, whereas previous work showed the fragment altered thousands of genes.
- Up-regulated Genes: The most significantly increased gene under FL-ApoE4 treatment was Gm33661 (154-fold), a predicted lncRNA. Pcsk5, involved in lipid metabolism, was also significantly up-regulated (22.5-fold).
- Opposing Inflammatory Profiles: Interestingly, FL-ApoE4 appeared to have a mild anti-inflammatory effect, down-regulating key cytokines such as Il27 (-5.69-fold) and Il23a (-4.00-fold). Conversely, the nApoE4$_{1-151}$ fragment up-regulated these same genes by 183-fold and 14.1-fold, respectively. A strong negative correlation (Pearson’s r = -0.7) was observed between the gene expression changes induced by the two forms.
Discussion and Future Directions
These results support the hypothesis that fragmentation is a literal "toxic gain-of-function." Cleavage does not merely deactivate the protein's lipid-transport role; it transforms it into a potent pro-inflammatory signal that migrates to the nucleus.
While the use of the BV2 mouse cell line is a limitation, the stark contrast in gene expression profiles provides a compelling case for the role of ApoE4 fragments in AD-related neuroinflammation. Future research must identify the specific proteases responsible for this cleavage in the human brain. Therapeutically, these findings suggest that specifically neutralizing the 151 amino-terminal fragment—rather than the full-length protein—may be a more precise and effective strategy for treating Alzheimer's Disease.
Summary updated